Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder

I. Wei Chang, Victor Chia Hsiang Lin, Wen Jen Wu, Peir In Liang, Wei Ming Li, Bi Wen Yeh, Hong Lin He, Alex Chien Hwa Liao, Ti Chun Chan, Chien Feng Li

研究成果: 雜誌貢獻文章

9 引文 (Scopus)

摘要

Purpose: Urothelial carcinoma of the urinary bladder and upper tract is prevalent. By subjecting a documented transcriptome data set of urothelial carcinoma of bladder (GSE31684) to data mining and focusing on genes linked to peptidase activity (GO:0008233), we recognized C1S as the most significantly upregulated gene related to an advanced tumor status and metastasis. We subsequently analyzed the association of both C1S mRNA and its encoded protein expression with the clinical and pathological significance. Materials and Methods: We used real-time reverse transcription polymerase chain reaction to detect C1S transcription levels in 20 cases each of urothelial carcinoma of bladder and upper tract. An immunohistochemical stain was conducted to determine C1s protein expression levels in patients with urothelial carcinoma of upper tract (n = 340) and urinary bladder (n = 295). Furthermore, we examined the correlation of C1s expression with clinicopathological characteristics, disease-specific survival, and metastasis-free survival. Results: C1S transcription levels were significantly high in patients with advanced-stage tumors of both groups (all P < .05). Immunohistochemical analysis revealed that C1s expression levels were significantly associated with adverse clinicopathological parameters in both groups of urothelial carcinoma (all P < .05). C1s overexpression predicted poor disease-specific and metastasis-free survival rates for both urothelial carcinoma groups in the univariate analysis, and it was also an independent prognostic factor in the multivariate analysis (all P < .05). Conclusions: C1s may play a pivotal role in urothelial carcinoma progress and can represent a vital prognostic marker and a promising new therapeutic target in urothelial carcinoma.
原文英語
頁(從 - 到)1396-1405
頁數10
期刊Journal of Cancer
7
發行號11
DOIs
出版狀態已發佈 - 一月 1 2016
對外發佈Yes

指紋

Complement C1
Urinary Tract
Urinary Bladder
Carcinoma
Neoplasm Metastasis
Data Mining
Survival
Transcriptome
Genes
Reverse Transcription
Neoplasms
Proteins
Peptide Hydrolases
Coloring Agents
Multivariate Analysis
Survival Rate
Polymerase Chain Reaction
Messenger RNA

ASJC Scopus subject areas

  • Oncology

引用此文

Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. / Chang, I. Wei; Lin, Victor Chia Hsiang; Wu, Wen Jen; Liang, Peir In; Li, Wei Ming; Yeh, Bi Wen; He, Hong Lin; Liao, Alex Chien Hwa; Chan, Ti Chun; Li, Chien Feng.

於: Journal of Cancer, 卷 7, 編號 11, 01.01.2016, p. 1396-1405.

研究成果: 雜誌貢獻文章

Chang, I. Wei ; Lin, Victor Chia Hsiang ; Wu, Wen Jen ; Liang, Peir In ; Li, Wei Ming ; Yeh, Bi Wen ; He, Hong Lin ; Liao, Alex Chien Hwa ; Chan, Ti Chun ; Li, Chien Feng. / Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. 於: Journal of Cancer. 2016 ; 卷 7, 編號 11. 頁 1396-1405.
@article{79f3b7d99a7b48a9891f52ef3ccc3bf8,
title = "Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder",
abstract = "Purpose: Urothelial carcinoma of the urinary bladder and upper tract is prevalent. By subjecting a documented transcriptome data set of urothelial carcinoma of bladder (GSE31684) to data mining and focusing on genes linked to peptidase activity (GO:0008233), we recognized C1S as the most significantly upregulated gene related to an advanced tumor status and metastasis. We subsequently analyzed the association of both C1S mRNA and its encoded protein expression with the clinical and pathological significance. Materials and Methods: We used real-time reverse transcription polymerase chain reaction to detect C1S transcription levels in 20 cases each of urothelial carcinoma of bladder and upper tract. An immunohistochemical stain was conducted to determine C1s protein expression levels in patients with urothelial carcinoma of upper tract (n = 340) and urinary bladder (n = 295). Furthermore, we examined the correlation of C1s expression with clinicopathological characteristics, disease-specific survival, and metastasis-free survival. Results: C1S transcription levels were significantly high in patients with advanced-stage tumors of both groups (all P < .05). Immunohistochemical analysis revealed that C1s expression levels were significantly associated with adverse clinicopathological parameters in both groups of urothelial carcinoma (all P < .05). C1s overexpression predicted poor disease-specific and metastasis-free survival rates for both urothelial carcinoma groups in the univariate analysis, and it was also an independent prognostic factor in the multivariate analysis (all P < .05). Conclusions: C1s may play a pivotal role in urothelial carcinoma progress and can represent a vital prognostic marker and a promising new therapeutic target in urothelial carcinoma.",
keywords = "C1S gene, Complement component 1s, Prognosis, Urothelial carcinoma",
author = "Chang, {I. Wei} and Lin, {Victor Chia Hsiang} and Wu, {Wen Jen} and Liang, {Peir In} and Li, {Wei Ming} and Yeh, {Bi Wen} and He, {Hong Lin} and Liao, {Alex Chien Hwa} and Chan, {Ti Chun} and Li, {Chien Feng}",
year = "2016",
month = "1",
day = "1",
doi = "10.7150/jca.15339",
language = "English",
volume = "7",
pages = "1396--1405",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "11",

}

TY - JOUR

T1 - Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder

AU - Chang, I. Wei

AU - Lin, Victor Chia Hsiang

AU - Wu, Wen Jen

AU - Liang, Peir In

AU - Li, Wei Ming

AU - Yeh, Bi Wen

AU - He, Hong Lin

AU - Liao, Alex Chien Hwa

AU - Chan, Ti Chun

AU - Li, Chien Feng

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose: Urothelial carcinoma of the urinary bladder and upper tract is prevalent. By subjecting a documented transcriptome data set of urothelial carcinoma of bladder (GSE31684) to data mining and focusing on genes linked to peptidase activity (GO:0008233), we recognized C1S as the most significantly upregulated gene related to an advanced tumor status and metastasis. We subsequently analyzed the association of both C1S mRNA and its encoded protein expression with the clinical and pathological significance. Materials and Methods: We used real-time reverse transcription polymerase chain reaction to detect C1S transcription levels in 20 cases each of urothelial carcinoma of bladder and upper tract. An immunohistochemical stain was conducted to determine C1s protein expression levels in patients with urothelial carcinoma of upper tract (n = 340) and urinary bladder (n = 295). Furthermore, we examined the correlation of C1s expression with clinicopathological characteristics, disease-specific survival, and metastasis-free survival. Results: C1S transcription levels were significantly high in patients with advanced-stage tumors of both groups (all P < .05). Immunohistochemical analysis revealed that C1s expression levels were significantly associated with adverse clinicopathological parameters in both groups of urothelial carcinoma (all P < .05). C1s overexpression predicted poor disease-specific and metastasis-free survival rates for both urothelial carcinoma groups in the univariate analysis, and it was also an independent prognostic factor in the multivariate analysis (all P < .05). Conclusions: C1s may play a pivotal role in urothelial carcinoma progress and can represent a vital prognostic marker and a promising new therapeutic target in urothelial carcinoma.

AB - Purpose: Urothelial carcinoma of the urinary bladder and upper tract is prevalent. By subjecting a documented transcriptome data set of urothelial carcinoma of bladder (GSE31684) to data mining and focusing on genes linked to peptidase activity (GO:0008233), we recognized C1S as the most significantly upregulated gene related to an advanced tumor status and metastasis. We subsequently analyzed the association of both C1S mRNA and its encoded protein expression with the clinical and pathological significance. Materials and Methods: We used real-time reverse transcription polymerase chain reaction to detect C1S transcription levels in 20 cases each of urothelial carcinoma of bladder and upper tract. An immunohistochemical stain was conducted to determine C1s protein expression levels in patients with urothelial carcinoma of upper tract (n = 340) and urinary bladder (n = 295). Furthermore, we examined the correlation of C1s expression with clinicopathological characteristics, disease-specific survival, and metastasis-free survival. Results: C1S transcription levels were significantly high in patients with advanced-stage tumors of both groups (all P < .05). Immunohistochemical analysis revealed that C1s expression levels were significantly associated with adverse clinicopathological parameters in both groups of urothelial carcinoma (all P < .05). C1s overexpression predicted poor disease-specific and metastasis-free survival rates for both urothelial carcinoma groups in the univariate analysis, and it was also an independent prognostic factor in the multivariate analysis (all P < .05). Conclusions: C1s may play a pivotal role in urothelial carcinoma progress and can represent a vital prognostic marker and a promising new therapeutic target in urothelial carcinoma.

KW - C1S gene

KW - Complement component 1s

KW - Prognosis

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84994344883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994344883&partnerID=8YFLogxK

U2 - 10.7150/jca.15339

DO - 10.7150/jca.15339

M3 - Article

AN - SCOPUS:84994344883

VL - 7

SP - 1396

EP - 1405

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 11

ER -